RLYB · Rallybio Corp · Executive Compensation
Market Cap
$88.26M
Shares
5.31M
Volume · Oct 2
7853
Avg daily vol (3M)
22.77K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Stephen Uden | Chief Executive Officer and President | $1,127,666 |
| Martin W. Mackay | Chairman, former Executive Chairman | $1,102,862 |
| Steven Ryder | Chief Medical Officer | $911,061 |
| Jonathan I. Lieber | M.B.A. Chief Financial Officer and Treasurer | $839,216 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Jonathan I. Lieber | M.B.A. Chief Financial Officer and Treasurer | $1,899,030 |
| Stephen Uden | Chief Executive Officer and President | $1,765,084 |
| Martin W. Mackay | Chairman, former Executive Chairman | $1,765,084 |
| Steven Ryder | Chief Medical Officer | $1,253,641 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Jeffrey M. Fryer | Former Chief Financial Officer and Treasurer | $1,398,174 |
| Martin W. Mackay | Executive Chairman and former Chief Executive Officer | $1,398,174 |
| Stephen Uden | Chief Executive Officer and President | $1,398,174 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Jeffrey M. Fryer | Former Chief Financial Officer and Treasurer | $2,894,420 |
| Stephen Uden | President, Chief Operating Officer and Chief Scientific Officer | $2,894,420 |
| Martin W. Mackay | Chief Executive Officer and Chairman | $2,894,420 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Jeffrey M. Fryer | Chief Financial Officer and Treasurer | $838,056 |
| Martin W. Mackay | Chief Executive Officer and Chairman | $838,056 |
| Stephen Uden | President, Chief Operating Officer and Chief Scientific Officer | $838,056 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Mohammad Hirmand, M.D. | Chief Medical Officer of the combined company | Appointed | 2026-06-01 |
| Brian Sun, J.D. | Chief Legal Officer of the combined company | Appointed | 2026-06-01 |
| Scott Lipman, M.B.A. | Chief Financial Officer and Chief Business Officer of the combined company | Appointed | 2026-06-01 |
| Athena Countouriotis, M.D. | Chair, President and Chief Executive Officer of the combined company | Appointed | 2026-06-01 |
| Kush Parmar | member of the Board and as Chair of the Nominating and Corporate Governance Committee of the Board | Resigned | 2024-09-17 |
| Martin Mackay, Ph.D. | Executive Chairman | Resigned | 2024-07-23 |
| Stephen Uden, M.D. | director | Appointed | 2023-06-29 |
| Martin Mackay, Ph.D. | Executive Chairman | Appointed | 2023-06-29 |
| Stephen Uden, M.D. | Chief Executive Officer | Appointed | 2023-06-29 |
| Jonathan I. Lieber | Chief Financial Officer and Treasurer | Appointed | 2023-01-31 |
| Wendy K. Chung, M.D., Ph.D. | director | Appointed | 2022-08-02 |